A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801)
| dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
| dc.contributor.author | GOMEZ, H. | |
| dc.contributor.author | NECIOSUP, S. | |
| dc.contributor.author | TOSELLO, C. | |
| dc.contributor.author | MANO, M. | |
| dc.contributor.author | BINES, J. | |
| dc.contributor.author | ISMAEL, G. | |
| dc.contributor.author | SANTI, P. X. | |
| dc.contributor.author | PINCZOWSKY, H. | |
| dc.contributor.author | NERON, Y. | |
| dc.contributor.author | FANELLI, M. | |
| dc.contributor.author | FEIN, L. | |
| dc.contributor.author | SAMPAIO, C. | |
| dc.contributor.author | LERZO, G. | |
| dc.contributor.author | CAPO, A. | |
| dc.contributor.author | ZARBA, J. J. | |
| dc.contributor.author | BLAJMAN, C. | |
| dc.contributor.author | VARELA, M. S. | |
| dc.contributor.author | MARTINEZ-MESA, J. | |
| dc.contributor.author | WERUTSKY, G. | |
| dc.contributor.author | BARRIOS, C. H. | |
| dc.date.accessioned | 2015-11-11T16:27:45Z | |
| dc.date.available | 2015-11-11T16:27:45Z | |
| dc.date.issued | 2013 | |
| dc.description.index | MEDLINE | |
| dc.identifier.citation | CANCER RESEARCH, v.73, suppl.24, 2013 | |
| dc.identifier.doi | 10.1158/0008-5472.SABCSI3-P4-12-26 | |
| dc.identifier.eissn | 1538-7445 | |
| dc.identifier.issn | 0008-5472 | |
| dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/12116 | |
| dc.language.iso | eng | |
| dc.publisher | AMER ASSOC CANCER RESEARCH | |
| dc.relation.ispartof | Cancer Research | |
| dc.rights | restrictedAccess | |
| dc.rights.holder | Copyright AMER ASSOC CANCER RESEARCH | |
| dc.subject.wos | Oncology | |
| dc.title | A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801) | |
| dc.type | conferenceObject | |
| dc.type.category | meeting abstract | |
| dc.type.version | publishedVersion | |
| dspace.entity.type | Publication | |
| hcfmusp.contributor.author-fmusphc | MAX SENNA MANO | |
| hcfmusp.description.issue | suppl 24 | |
| hcfmusp.description.volume | 73 | |
| hcfmusp.origem | WOS | |
| hcfmusp.origem.wos | WOS:000209496902032 | |
| hcfmusp.publisher.city | PHILADELPHIA | |
| hcfmusp.publisher.country | USA | |
| relation.isAuthorOfPublication | 1541ce2f-dafd-4094-b650-ef95fa7da1e3 | |
| relation.isAuthorOfPublication.latestForDiscovery | 1541ce2f-dafd-4094-b650-ef95fa7da1e3 |